Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

(2015) T Macarulla et al.   BRITISH JOURNAL OF CANCER

Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients

(2015) Raji Shameem et al.   CANCER INVESTIGATION

Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis

(2015) Omar Abdel-Rahman et al.   Expert Review of Anticancer Therapy

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity

(2015) K E Duncan et al.   EYE

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

(2014) A. W. Tolcher et al.   ANNALS OF ONCOLOGY

Incidence of Mucositis in Patients Treated With Temsirolimus-Based Regimens and Correlation to Treatment Response

(2014) X. Liu et al.   ONCOLOGIST

The MEK1/2 Inhibitor AS703026 Circumvents Resistance to the BRAF Inhibitor PLX4032 in Human Malignant Melanoma Cells

(2013) Seong Joon Park et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials

(2013) Aung Naing   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

(2013) Erika Martinelli et al.   INTERNATIONAL JOURNAL OF CANCER

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

(2012) A. Awada et al.   EUROPEAN JOURNAL OF CANCER

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

(2011) K. P. Hoeflich et al.   CANCER RESEARCH

PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

(2011) Giovanni Ligresti et al.   CELL CYCLE

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

(2010) Kihyun Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma

(2010) Hung Huynh   CANCER

Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models

(2010) Qing Chang et al.   CANCER BIOLOGY & THERAPY

MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies forKRASMutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy

(2010) Juyong Yoon et al.   CANCER RESEARCH

Combined Inhibition of MEK and mTOR Signaling Inhibits Initiation and Progression of Colorectal Cancer

(2009) Yan-Jie Zhang et al.   CANCER INVESTIGATION

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer

(2009) Ning Jin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

(2009) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-Resolution Melting Analysis for Rapid Detection ofKRAS, BRAF,andPIK3CAGene Mutations in Colorectal Cancer

(2008) Lisa Simi et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers

(2008) Zhi Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cotargeting survival signaling pathways in cancer

(2008) Steven Grant   JOURNAL OF CLINICAL INVESTIGATION

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

(2008) Carolyn Waugh Kinkade et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

(2008) Arkaitz Carracedo et al.   JOURNAL OF CLINICAL INVESTIGATION

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY